ICYMI: Belimumab in Pregnancy? a study of 13 pregnancies in 13 pts, mean age 38 yrs.. There were 11 live births, 1 case omphalitis (recovered w Abx) . No fetal anomalies found. 6 pts (46%) w/ Hx of recurrent pregnancy loss, four had live births on BEL https://t.co/FJJhepa25M

• https://bit.ly/3stCEWo

FDA JAKi Warnings, 2nd Panel of rheumatologists weigh in on this. Drs. Cush, Dao, Tate, Sparks, Shergy. https://t.co/eETzP8DspC via @YouTube #RheumNow @KDAO2011 @uptoTate @jeffsparks @WilliamShergy https://t.co/iqxFQjJQ0l

• https://bit.ly/3tiUYSy

Do you subscribe to our weekly podcast? It’s available wherever you download your podcasts—just search RheumNow. And, of course, find it on the site each Friday! https://t.co/wjBWCrKL34 https://t.co/MZzpNIpTv1

• https://bit.ly/3pjQqJ2

ICYMI: Using inpatient hospital records of 1.9 million SLE pts, the mortality of hospitalized #SLE changed little from 2006-2016;mortality dropped from 2.2% to 1.5% - with most of this decline between 2006-‘08 and no change since. Racial disparities seen. https://t.co/UUsJYFxQS4

• https://bit.ly/2V7lFgi

ICYMI Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors https://t.co/omeZyprT96 https://t.co/UGBlb9m5bS

• https://bit.ly/2WKzd1J

Highly allergic can safely get the COVID Vax. Israeli study of 8102 pts w/ allergies recv Pfizer mRNA vax - 429 were highly allergic-->98% of the highly allergic had no allergic rxns, 1% mild allergic resp & 3 anaphylactic rxns Rx w/ EPI, none hospitalized https://t.co/ATYs5R5AQC https://t.co/owNEACH1pe

• https://bit.ly/3mYKrKX

New podcast available! Download wherever you get your podcasts. https://t.co/4jTBhYDzRn https://t.co/DUWVD89JJ5

• https://bit.ly/3yNimZs

ICYMI: FDA slaps new BOXED warning revision on ALL JAK inhibitors (Xeljanz, Olumiant, Rinvoq) after final revew of the Pfizer Oral Surveillance study. New warnings for incr risk of MI, CVA, VTE, lymphoma & death see w/ BOTH dose of tofacitinib. https://t.co/tvTv40oy59

• https://bit.ly/3jAFqX7

500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RBM1xJ https://t.co/woSafvVsmA

• https://bit.ly/3Boev6I

Not All Immunosuppression Alters Vaccine Immunogenicity https://t.co/I9sShpMLBO https://t.co/oz9Qp1HM1e

• https://bit.ly/3BAQNEz

FDA JAKi Warnings, 2nd Panel of rheumatologists weigh in on this. Drs. Cush, Dao, Tate, Sparks, Shergy. https://t.co/0WqeV6jKex via @YouTube #RheumNow @KDAO2011 @uptoTate @jeffsparks @WilliamShergy

• https://youtu.be/XNg97wWaQig

FDA JAK inhibitor warnings and what it means (also: what do you think?); other news released this week; and, two questions submitted from listeners. Dr. Cush discusses this and more in this week's podcast. https://t.co/4jTBhYDzRn https://t.co/lMpl2IOeXe

• https://bit.ly/3yNimZs

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors https://t.co/omeZyprT96 https://t.co/zXlGpEK6cC

• https://bit.ly/2WKzd1J

FORWARD prospective registry showed Obesity to be associated with a substantially higher risk of incident chronic opioid use (HR adj 1.74). Approximately 1 in 4 cases of incident strong opioid use can be attributable to obesity ((HRadj 2.11) https://t.co/R0KhH4b05g https://t.co/HGHeqh4B0c

• https://bit.ly/3mXJ7Ir

PhIII trial of Baricitinib vs placebo in hospitalized COVID-19 pts (91% steroids, 13% remdesivir). While no diff (28 vs 30%) in primary outcome (O2, ventilation, death). BARI had signif better Mortality @28d (8 vs 13%) & 60d (10 vs 15%) w/ no incr in VTE https://t.co/AjoRgEKW8G

• https://bit.ly/3yFBDfh